Accessibility Menu
Oaktree Acquisition Corp. III Life Sciences logo

Oaktree Acquisition Corp. III Life Sciences(NASDAQ) OACC

Market Cap$264.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+7%
5 YearN/A
1 Year+3%
1 Month+0%
$10.78
+0.37%
+0.04Today
Oaktree Acquisition Corp. III Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 10.742026-08-24
Oaktree Acquisition Corp. III Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.56%USD 10.802026-08-17
1 month+0.28%USD 10.712026-07-24
3 month+0.51%USD 10.692026-05-26
Year to date+1.51%USD 10.582025-12-31
1 year+3.17%USD 10.412025-08-22
Since inception+7.4%USD 10.002024-12-16

Oaktree Acquisition Corp. III Life Sciences Financials at a Glance

Market Cap

$264.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$6.75M

EPS (TTM)

$0.27

P/E Ratio

39.08

Dividend

$0.00

Beta (Volatility)

0.12 (Low)

Price

$10.78

Volume

423

Open

$10.78

Previous Close

$10.78

Daily Range

$10.78 - $10.78

52-Week Range

$10.36 - $10.88

Estimated Earnings Date

Oct 1, 2025

OACC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences finds and funds healthcare companies. It searches for medical businesses needing money to grow. This helps bring new treatments and tools to patients.

Searching for Healthcare Partners

  • Business Combination Services: Operates as a blank check company, which is a shell corporation designed to merge with or acquire another business.
  • Target Identification: Focuses on the biopharmaceutical, medical device, and specialized healthcare sectors.
  • Geographic Scope: Concentrates search efforts on potential target businesses located in North America and Europe.

Recent Strategic Milestones

  • Completed its initial public offering on Oct. 25, 2024.
  • Raised $175 million by selling 17.5 million units at $10.00 per unit.
  • Sold 583,981 private placement units to its sponsor in Oct. 2024 to generate additional working capital.

Specialized Focus in Life Sciences

Oaktree Acquisition Corp. III Life Sciences uses a trust account to store capital raised during its initial public offering. This structure ensures that funds are available for a merger with a healthcare business in North America or Europe.

Tracking the Trust Account

  • Net income reached $1.6 million for the three-month period ended June 30, 2026.
  • Interest income from the trust account totaled $3.7 million for the six-month period ended June 30, 2026.
  • Cash held in the trust account was $205.3 million as of June 30, 2026.
  • The company has until Oct. 25, 2026, to complete a business combination.

Bottom Line

Oaktree Acquisition Corp. III Life Sciences serves as a specialized financial bridge for private healthcare firms looking to enter public markets. It maintains a large capital pool while evaluating potential partners before its 2026 deadline.

AI Generated • Aug 13, 2026

Industry

Banks

Sector

Financials

Employees

3

CEO

Zaid Pardesi, MBA

Website

www.oaktreeacquisitioncorp.com/oac-iii

Headquarters

Los Angeles, CA 90071, US

OACC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

3.46%

Return on Capital

-0.61%

Return on Assets

3.27%

Earnings Yield

2.56%

Dividend Yield

0.00%

Payout Ratio

62.89%

Stock Overview

Market Cap

$264.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

24.58M

Volume

423

Avg. Volume

22.44K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.20M

EBITDA

-$1.20M

Operating Cash Flow

-$455.69K

Capital Expenditure

$3.00

Free Cash Flow

-$455.69K

Cash & ST Invst.

$1.18M

Total Debt

$11.82K

Oaktree Acquisition Corp. III Life Sciences Performance Analysis

Oaktree Acquisition Corp. III Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Oaktree Acquisition Corp. III Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Oaktree Acquisition Corp. III Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD 0.05N/A
20252025-12-31USD 0.30447.0%
Oaktree Acquisition Corp. III Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.0%
Q42025-12-31-9.0%
Q12026-03-31-17.6%
Q22026-06-3016.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$264.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$88.01M

N/A

Employees

3

N/A

Net Income

$1.60M

-14.4%

EBITDA

-$261.96K

+2.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.18M

-14.8%

Total Debt

$11.82K

+0.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$11.82K

+0.0%

Return on Assets

3.27%

N/A

Return on Invested Capital

-0.59%

N/A

Free Cash Flow

-$97.26K

+26.3%

Operating Cash Flow

-$97.26K

+26.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SOULSoulpower Acquisition Corp.
$10.45+0.00%
FACTFACT II Acquisition Corp
$10.69+0.00%
PMTRPerimeter Acquisition Corp. I Class A Ordinary Shares
$10.40-0.10%
COPLCopley Acquisition Corp
$10.52-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$213.05+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.09+0.01%
INTCIntel
$87.48+0.00%
BITOProShares Trust - ProShares Bitcoin ETF
$10.66+0.00%

Questions About OACC

What is the current price of Oaktree Acquisition Corp. III Life Sciences?

Oaktree Acquisition Corp. III Life Sciences is trading at $10.78 per share.

What is the 52-week range for Oaktree Acquisition Corp. III Life Sciences?

Over the past 52 weeks, Oaktree Acquisition Corp. III Life Sciences has traded between $10.36 and $10.88.

How much debt does Oaktree Acquisition Corp. III Life Sciences have?

As of the most recent reporting period, Oaktree Acquisition Corp. III Life Sciences reported total debt of $11.82K.

How much cash does Oaktree Acquisition Corp. III Life Sciences have on hand?

Oaktree Acquisition Corp. III Life Sciences reported $1.18M in cash and cash equivalents in its most recent financial results.

What is Oaktree Acquisition Corp. III Life Sciences’s dividend yield?

Oaktree Acquisition Corp. III Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services